Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma

Article Tools MOLECULAR TUMOR BOARD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00093 JCO Precision Oncology no. 7 (2023) e2200093. Published online February 14, 2023. PMID: 36787506 Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma Daniel A. King , MD, PhD1xDaniel A. KingSearch for articles by this author; Julianna J. Weiel, MD2,3xJulianna J. WeielSearch for articles by this author; Rochelle Reyes , PA-C4xRochelle ReyesSearch for articles by this author; Meredith Mills , BA5xMeredith MillsSearch for articles by this author; Antonita Itchon, PA-C5xAntonita ItchonSearch for articles by this author; George A. Fisher , MD, PhD5xGeorge A. FisherSearch for articles by this author; James M. Ford , MD5xJames M. FordSearch for articles by this author; and Carlos J. Suarez , MD2xCarlos J. SuarezSearch for articles by this author Show More 1Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY2Department of Pathology, Stanford University School of Medicine, Stanford, CA3Department of Pathology, Billings Clinic, Billings, MT4Early Drug Development Group, Stanford Cancer Institute, Stanford, CA5Division of Oncology, Department of Internal Medicine, Stanford University, Stanford, CA*D.A.K. and J.J.W. contributed equally to this work. https://doi.org/10.1200/PO.22.00093 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Daniel A. King, Julianna J. Weiel, George A. Fisher, James M. Ford, Carlos J. SuarezAdministrative support: Rochelle Reyes, Meredith Mills, Antonita ItchonProvision of study materials or patients: Rochelle Reyes, George A. Fisher, James M. Ford, Carlos J. SuarezCollection and assembly of data: All authorsData analysis and interpretation: Daniel A. King, Julianna J. Weiel, George A. Fisher, James M. Ford, Carlos J. SuarezManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Daniel A. KingStock and Other Ownership Interests: IlluminaHonoraria: Skysis, Ipsen, Omni HealthGeorge A. FisherStock and Other Ownership Interests: Seattle GeneticsHonoraria: eChinaHealthConsulting or Advisory Role: Merck, Taiho Pharmaceutical, Ipsen, Genentech/RocheResearch Funding: Genentech/Roche (Inst), Merck (Inst)Travel, Accommodations, Expenses: Merck, Roche/GenentechOther Relationship: CytomX Therapeutics, Silenseed, AstraZeneca, Terumo Clinical Supply, Taiho Pharmaceutical, Hutchison MediPharmaJames M. FordThis author is the Editor-in-Chief of JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Genentech (Inst), AstraZeneca (Inst), Puma Biotechnology (Inst), Pfizer (Inst), Merus (Inst), Bayer (Inst), Incyte (Inst)No other potential conflicts of interest were reported.